Urodynamix Technologies Ltd.
TSX VENTURE : URO

Urodynamix Technologies Ltd.

June 10, 2008 19:15 ET

Urodynamix Appoints Vice President of Business Development

VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 10, 2008) - Urodynamix Technologies Ltd. (TSX VENTURE:URO) today announced the appointment of Greg Gauthier as Vice President of Business Development.

With over 20 years of experience in the pharmaceutical and medical device sectors, Mr. Gauthier has held progressive sales and business development positions with industry leaders across North America and Europe including Baxter Healthcare Corp., Siemens Healthcare, C. R. Bard Inc., AmerisourceBergen Corp. and Alaris Medical Systems (acquired by Cardinal Health Inc. in 2004).

Mr. Gauthier has extensive experience taking new products into the healthcare market and aggressively executing innovative business development and joint venture strategies. He has been responsible for a number of successful marketing campaigns and new product introductions, successfully negotiating distribution agreements, managing distribution channels and establishing global dealer networks. Mr. Gauthier is a graduate of the University of Waterloo.

"We are very pleased to have Greg join the management team of Urodynamix," said Barry Allen, President and CEO. "A critical part of our strategy involves partnering with healthcare and medical device companies to bring innovative new products to market. We are confident that Greg will be instrumental in commercializing our technologies and contribute importantly to our business strategy and growth."

As part of his compensation, the Company has granted 200,000 incentive stock options to Mr. Gauthier. The stock options are being offered in conformance with TSX Venture Exchange regulations as incentive compensation and have a term of five years and an exercise price of $0.21 per share.

About Urodynamix Technologies Ltd.

Urodynamix Technologies is a Canadian medical device company developing and commercializing non-invasive medical technology based on proprietary applications of near-infrared spectroscopy (NIRS). The Company is currently focused on products that aid in the diagnosis and treatment of urinary incontinence, lower urinary tract symptoms, prostate cancer, benign prostatic hyperplasia, and traumatic increases in intra-abdominal pressure that cause abdominal compartment syndrome. Urodynamix's breakthrough medical technology has the potential to beneficially affect more than 200 million people worldwide.

Certain information contained in this press release may be forward-looking and is subject to unknown risks, which could cause actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information